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Abstract
Background: Following the initial identification of the 2019 coronavirus disease (covid-19), the subsequent months
saw substantial increases in published biomedical research. Concerns have been raised in both scientific and lay
press around the quality of some of this research. We assessed clinical research from major clinical journals,
comparing methodological and reporting quality of covid-19 papers published in the first wave (here defined as
December 2019 to May 2020 inclusive) of the viral pandemic with non-covid papers published at the same time.
Methods: We reviewed research publications (print and online) from The BMJ, Journal of the American Medical
Association (JAMA), The Lancet, and New England Journal of Medicine, from first publication of a covid-19 research
paper (February 2020) to May 2020 inclusive. Paired reviewers were randomly allocated to extract data on
methodological quality (risk of bias) and reporting quality (adherence to reporting guidance) from each paper using
validated assessment tools. A random 10% of papers were assessed by a third, independent rater. Overall
methodological quality for each paper was rated high, low or unclear. Reporting quality was described as
percentage of total items reported.
Results: From 168 research papers, 165 were eligible, including 54 (33%) papers with a covid-19 focus. For
methodological quality, 18 (33%) covid-19 papers and 83 (73%) non-covid papers were rated as low risk of bias, OR
6.32 (95%CI 2.85 to 14.00). The difference in quality was maintained after adjusting for publication date, results,
funding, study design, journal and raters (OR 6.09 (95%CI 2.09 to 17.72)). For reporting quality, adherence to
reporting guidelines was poorer for covid-19 papers, mean percentage of total items reported 72% (95%CI:66 to 77)
for covid-19 papers and 84% (95%CI:81 to 87) for non-covid.
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Conclusions: Across various measures, we have demonstrated that covid-19 research from the first wave of the
pandemic was potentially of lower quality than contemporaneous non-covid research. While some differences may
be an inevitable consequence of conducting research during a viral pandemic, poor reporting should not be
accepted.
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Background
The severe acute respiratory syndrome coronavirus 2 (SARS
COV-2), and the resulting clinical coronavirus disease 2019
(covid-19) have disrupted all aspects of healthcare [1]. As the
pathogen is new, in the first wave of viral infections, research
was urgently needed to influence policy and practice. Al-
though we have made substantial progress, there is still
much we do not know about the virus and the necessary re-
search spans many methodological approaches including ob-
servational epidemiology, assessment of the accuracy of test
strategies, trials of interventions and many others.
The main platform for sharing results of scientific re-
search remains the peer reviewed, biomedical journal. Bio-
medical publishers reported a substantial increase in
submissions in early 2020, with most of the content re-
lated to covid-19. Journals responded to the increasing
volume of covid-19 research with rapid publication of
these papers [2, 3]. However, there is concern that in the
rush to share data, some good practice aspects of research
design, conduct and interpretation may have been lost [4].
Arguments around the integrity and quality of covid-19
research have been rehearsed in the lay and scientific press
[5, 6]. While these important issues have generated sub-
stantial copy, there has been little quantitative, scientific
description of research quality as a basis for this discourse.
There are many aspects of a scientific paper that con-
tribute towards the overall ‘quality’ [7]. Two of the most
important are the design and conduct of the research
(methodological quality) and the way the study and re-
sults are communicated (reporting quality) [8, 9]. These
aspects of scientific process are complementary. Meth-
odological quality ensures that the results presented are
robust and biases are minimised, while reporting quality
ensures transparency and aids interpretation.
We aimed to assess methodological quality (risk of
bias) and reporting quality (compliance with reporting
guidelines) for papers published in the highest impact
biomedical journals during the first wave (here defined
as December 2019 to May 2020 inclusive) of the covid-
19 pandemic. We compared results for covid-19 and
contemporaneous non-covid research.
Methods
Although not a systematic review in the classical sense,
where appropriate we adhered to the relevant sections of
the Preferred Reporting Items for Systematic reviews
and Meta-analyses (PRISMA) guidance [10]. No ethical
approvals were required. Full details on methods are
available in the study protocol and additional files (Add-
itional Files 1: Supplementary text S1–3).
There was no funding source for this study. The corre-
sponding author had full access to all the data in the
study and had final responsibility for the decision to sub-
mit for publication.
Search strategy
We included the following journals, chosen as represent-
ing the highest impact clinical research titles in the cat-
egory of ‘Medicine, General and Internal’ (based on
Journal Citation Reports 2018 category (Clarivate Ana-
lytics)): The BMJ (British Medical Association), The Jour-
nal of the American Medical Association (JAMA,
American Medical Association), The Lancet (Elsevier)
and The New England Journal of Medicine (NEJM, Mas-
sachusetts Medical Society). We favoured these four ti-
tles as they publish weekly print editions, have
international readerships and are generally considered to
have the highest publication standards. These were also
some of the first journals to publish clinical research on
covid-19 during the first wave of the pandemic.
Each print journal was hand searched by a single re-
viewer, beginning from January 2020 to identify the first
clinical covid-19 research papers. These publications
were the inception point for further hand searching to
collate all research papers from that journal. As an in-
ternal validity check, the journals’ online search facility
and/or any specific covid-19 resource hubs were checked
to ensure no relevant content had been missed. Paper
selection was from the first week that the relevant jour-
nal published a covid-19 related clinical research paper
and concluded on Sunday 17th of May inclusive. On this
date, journal websites were searched for all covid-19 pa-
pers available online prior to print. These dates were
chosen to represent the first wave of the covid-19
pandemic.
Inclusion and exclusion criteria
We assessed all articles labelled as original clinical re-
search, including Brief Reports. We did not include non-
research content such as editorials or commentary.
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Within the original clinical research remit, we excluded
papers that were not suitable for assessment with our
chosen quality tools, for example pre-clinical or transla-
tional science. Decisions on exclusion were made by
raters as part of the initial assessment of potentially eli-
gible papers.
We classified included papers based on the primary
study method and this classification informed the choice
of the quality assessment tools used. We pre-defined six
categories chosen to encompass the most commonly
used clinical research designs: diagnostic test accuracy;
observational studies (subdivided into case-study/case-
series, case-control, cohort and cross-sectional); progno-
sis; qualitative; randomised controlled trials (RCT); and
systematic review.
We created two groups to facilitate comparisons,
‘covid-19’ research and ‘non-covid’. The covid-19 label
was applied where the exposure, intervention, test or
outcomes related to covid-19/SARS COV-2.
Risk of bias and reporting
We assessed the two quality measures (risk of bias and
reporting) separately, using validated tools suited to our
pre-specified study designs [10–21]. Choice of tool was
based on published validation, availability of training
materials and guidance. We favoured those tools used by
Cochrane [22] and featured on the EQUATOR resource
(Enhancing the QUAlity and Transparency Of health
Research) [23] where possible. For RCTs, we used the
Cochrane risk of bias [11] tool and the Consolidated
Standards of Reporting Trials (CONSORT) checklist
[12]. For observational studies, we used the National
Heart Lung and Blood Institute tool (NHLBI) [13] and
the Strengthening the Reporting of Observational Stud-
ies in Epidemiology (STROBE) [14](Table 1). To facili-
tate comparisons where general and specialist guidance
was available, we used the more general checklists
(Table 1).
For methodological quality assessment, we assessed
risk of bias at the level of pre-specified domains and at
the level of the complete paper with a final overall
grading of ‘low’, ‘high’ or ‘unclear’ risk of bias. Decisions
on overall risk of bias were made by the rater pairs, in-
formed by the domain level assessments. Overall risk
was not defined by a threshold of number of individual
domains that scored low or high risk; rather, overall risk
of bias was considered on a paper by paper basis.
For reporting quality, we assessed adherence with
reporting guidance at an individual item level with
reporting scored as ‘yes’ (where reporting was deemed
adequate), ‘no’ or ‘not applicable’. This allowed calcula-
tion of proportional adherence (percentage of total items
reported) as the number of adequately reported items
against the number of relevant items for the paper.
Data extraction
The team were all researchers with experience and train-
ing in meta-research. From a pool of 12 reviewers, we
created six reviewer pairs, consisting of one experienced
and one less experienced researcher. Each pair had re-
course to the senior author (TQ) for advice or where
there was disagreement on assessment. Assessor pairs
were allocated a test set of six papers (covid-19 and
non-covid) for review and calibration within pairs and
within the group. Pairs were then randomly allocated eli-
gible papers in blocks. Reviewer pairs extracted descrip-
tive and outcomes data independently and compared
results. In the case of disagreement, papers were dis-
cussed with a third reviewer (the experienced reviewer
from another reviewer pair). As a validity check, a ran-
dom selection of 10% of the included papers was se-
lected for further review by an independent reviewer (an
experienced reviewer from the pool of reviewers, that
was not part of the respective reviewer pair). We col-
lected data on domain level disagreement requiring dis-
cussion for each assessor pair to calculate percentage
disagreement within the group. All random allocation
used the random.org online resource [24].
Reviewers used standardised data extraction forms,
piloted on two studies (one RCT, one observational) [25,
26]. We collated the following study-level details: jour-
nal, study design, whether the paper was identified as a
Table 1 Tools used to assess quality (risk of bias) and reporting





Cochrane RoB Randomisation, allocation, blinding (participants), blinding (outcomes), incomplete outcomes,
selective reporting, other
CONSORT
Observational NHLBI Question, population, exposure, outcomes, confounding, other STROBE
Test accuracy QUADAS2 Patient selection, index test, reference standard, flow and timing, generalisability, other STARD
Systematic
review
AMSTAR2 Design and protocol, search strategy, paired extraction, inclusion/exclusion, risk of bias, meta-analysis,
conflicts of interest, other
PRISMA
Qualitative CASP Design, recruitment, data collection, relationships, analysis, other COREQ
Prognosis PROBAST Participants, predictors, outcomes, analysis, generalisability, other TRIPOD
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‘Brief Report’ or equivalent, the exposure of interest (or
intervention, or index test), covid-19 status, the total ‘n’
included in the study at baseline (for a systematic review
this was taken as the number of included papers),
follow-up (time from first measure to last measure for
primary outcome, quantified in weeks) and funding
source (academic or industry). We assessed the timing
of publication, comparing papers published before a
midpoint of April 12, 2020 (10 weeks after the date of
the first covid-19 publication), to publication after this
date. We assessed whether the paper was framed as hav-
ing a positive or neutral result (using a method de-
scribed previously [27]), had an accompanying editorial,
or had retraction or serious correction (full definitions
in Additional File 1: Supplementary text S3).
Outcomes
Our primary outcome was methodological quality, based
on assessment of overall risk of bias for each included
paper. Our co-primary outcome was reporting quality,
based on adherence to reporting guidelines and quanti-
fied as proportion of relevant reporting items completed
for each included paper.
Data synthesis and analyses
We locked the database on 11th of June when the last
review was submitted, and quality control checks were
complete. A statistician independent of the main review
group conducted the analyses. Covid-19 status was nu-
merically coded so that this variable was not obvious to
the statistician.
We tabulated descriptive statistics for covid-19 and
non-covid research, comparing features of the included
papers using non-parametric and proportional statistics
as required. We collated data on inter-rater agreement
from reviewer pairs to calculate summary reliability for
the team.
We created graphical illustrations of methodological
and reporting quality at paper level and in aggregate
[28]. We created modified star plots, to describe domain
level and overall risk of bias and reporting adherence for
covid-19 and non-covid papers. For each domain, we
calculated difference in score between covid-19 and
non-covid with corresponding uncertainty (95% confi-
dence interval [95%CI]) using an approach that
accounted for small samples sizes [29].
We compared proportions of ‘low risk of bias’ in
covid-19 and non-covid research across all included pa-
pers. We fitted a mixed effects logistic regression de-
scribing the odds of study level low risk of bias, where
the rater pairs were fitted as a random effect to control
for the heterogeneity introduced by scorers. The multi-
variable analysis was adjusted for time of publication,
funder (academic or industry), study results (positive or
negative), study design and journal. Stata version 15
(StataCorp) was used for the primary quantitative
analyses.
Results
We assessed 168 titles and included 165 research papers
(Fig. 1). The research method differed between covid-19
and non-covid papers. Covid-19 papers were less likely
to be based on RCTs (n = 6 (11%) for covid-19 v n = 60
(53%), difference 42% (95%CI 28 to 53)) and more likely
to use case series or other observational designs (n = 46
(85%) for covid-19 papers v n = 37 (32%), difference 52%
(95%CI 37 to 63)) (Fig. 2).
Covid-19 papers were more likely to be published in
Brief Report format (30% for covid-19 v 5%, difference
25% (95%CI 13 to 38)), to have an accompanying editor-
ial (57% for covid-19 v 38%, difference 18% (95%CI 2 to
33)) and to have a retraction or major post-publication
correction (13% for covid-19 v 0%, difference 13%
(95%CI 6 to 24)). Covid-19 papers had smaller sample
size (median 96 participants for covid-19 v 815 partici-
pants, P < 0.0001) and shorter follow-up (median 4 weeks
for covid-19 v 52 weeks, P < 0.0001) (Table 2).
Agreement within rater pairs was 85% for studies
assessed using the Cochrane risk of bias tool, 92% CON-
SORT, 86% NHLBI observational research tool, 90%
STROBE.
Aggregate and domain level, risk of bias charts and do-
main level modified star charts for RCTs and observa-
tional studies are presented in Figs. 3a,b and 4a,b and
Additional File 1: Figs. S1-S10.
Outcome 1: Methodological quality
Overall 101 of 165 studies (61%, 95%CI 50–74) were
rated as a low risk of bias. Of the non-covid studies, 83
(73%, 95%CI 64 to 81) were rated as low risk of bias,
compared to 18 (34%, 95%CI 22 to 48) in the covid-19
group (difference 65%, 95%CI 50–75).
Covid-19 study status was associated with study-level
risk of bias. Low risk of bias was 6 times more common
in the non-covid group than the covid-19 group (OR
6.3, 95%CI 2.9 to 14.0; p < 0.001). Bias differed between
study designs. Compared to observational designs, RCTS
were almost three times more likely to have low risk of
bias (OR 3.0, 95%CI 1.4 to 6.2; p = 0.004). The time of
publication, the journal of publication, the study design,
study findings and source of funding were all not associ-
ated with study level risk of bias.
In multivariable analysis, covid-19 papers remained
associated with almost six times higher risk of bias
(aOR = 6.1, 95%CI 2.1–17.7; p = 0.001) with none of
the other covariates exhibiting evidence of association
with risk of bias.
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Differences were still evident when analyses were restricted to
RCTs or observational studies only. For RCTs, low risk of bias
was more common in non-covid papers (46 papers, 77%) than
covid-19 papers (1 paper, 17%) (difference 60%, 95%CI 19–76).
Low risk of bias in observational studies was also more com-
mon in non-covid studies (23 papers, 61%) than in covid-19
studies (15 papers, 32%) (difference 29%, 95%CI 8–47).
All domains for observational studies and all but one do-
main for RCTs suggested lower quality scores in the covid-
19 papers, although with small sample sizes not all reached
significance at the conventional level (Figs. 3a,b and 4a,b).
Outcome 2: Reporting quality
Proportional adherence to reporting guidelines differed be-
tween covid-19 and non-covid research. Mean percentage ad-
herence to reporting guidance for non-covid was higher (84%,
95%CI 81 to 87) than for covid-19 studies (71%, 95%CI 66 to
77), with a mean difference of 13% (95%CI 0 to 27).
In analyses restricted to RCTs (CONSORT) and observa-
tional studies (STROBE), differences between covid-19 and
non-covid research were apparent but did not reach statis-
tical significance. For RCTs, mean adherence to reporting
guidelines for non-covid studies was 90% and for covid-19
papers this was 87% (difference 3%, 95%CI − 12 to 43). For
observational studies, mean adherence for non-covid studies
was 75% (95%CI 69 to 81) and for covid-19 studies was 69%
(95%CI 63 to 75) (difference 6%, 95%CI − 14 to 24).
All reporting domains for observational studies sug-
gested lower quality scores in the covid-19 papers, differ-
ences were less obvious for RCT reporting and small
sample sizes preclude meaningful comparative testing at
this level (Additional File 1: Figs. S9–10).
Fig. 1 PRISMA flow diagram describing search strategy and inclusion. Flow diagram illustrating literature search and results. NB The Lancet
published two data modelling covid-19 research papers in February 2020; these did not meet our definition of clinical research and so first paper
included was March
Fig. 2 Comparing published covid-19 and non-covid research using the classical ‘evidence pyramid’ hierarchy. NB For this illustration, the
category ‘observational’ is further divided into cases series and case control/cohort. Not all of our chosen research designs feature on the classical
evidence hierarchy pyramid. All differences are significant at P < 0.05
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Discussion
In our analysis of 168 clinical research papers published
across the four highest impact medical journals during the
first wave of the pandemic, we found that papers with a
covid-19 focus differed from other published research in
many ways—smaller sample size, shorter follow-up and
greater proportion of case-series and other observational
designs. Some of these differences are understandable for re-
search describing the first wave of a novel pathogen and the
research community has learned much about the virus since
we completed our review. More concerning was the sugges-
tion of poorer methodological quality (risk of bias) and
poorer reporting of the published covid-19 research. Given
the time pressures to produce data and the novelty of the
virus, some pragmatism can perhaps be allowed around re-
search design, for example it seems intuitive that the first pa-
pers describing a new pathogen are more likely to be
descriptive. However, there is no reason to sacrifice compre-
hensive, transparent reporting.
In a time-sensitive publishing space, some may argue
that publication standards may have been relaxed for pub-
lications on covid-19 during the first wave, with the antici-
pation that later papers would be more robust. We would
argue that there is a scientific and ethical imperative to
maintain standards of conduct and reporting. We ex-
plored the effect of time, and within our first wave sam-
pling frame, we found that publication date did not have a
major effect on quality. Many of the covid-19 papers were
published as ‘Brief Report’ format. Limits on word count
could compromise quality, but we did not find that format
of submission explained variation in scores. Planning, con-
ducting and reporting a trial take time and it seems intui-
tive that early covid-19 research may favour observational
designs. However, our finding of lower quality in covid-19
was not solely driven by an excess of early observational
studies. Observational studies were seen throughout the
period of assessment, and within those observational pa-
pers, quality was poorer for covid-19 papers. Regardless
Table 2 Comparing paper level characteristics of published






Randomised controlled trial 6 (11%) 60 (53%)
Observational 46 (85%) 37 (32%)
Systematic reviews 1 (2%) 11 (10%)
Test accuracy 0 (0%) 4 (4%)
Other 1 (2%) 2 (2%)
Content median (IQR)
Total number included 96 (16.5 to 762) 815 (219 to 4893)*
Follow-up (weeks) 4 (3 to 7) 52 (28 to 116)*
Positive result, n (%) 7 (13%) 74 (65%)*
Industry funding, n (%) 2 (4%) 31 (27%)*
Post-publication, n (%)
Brief report format 16 (30%) 6 (5%)*
Editorial 31 (57%) 43 (38%)**
Correction/retraction 7 (13%) 0 (0%)*
*Difference p < 0.0001
**Difference p < 0.05
Fig. 3 a, b Risk of bias charts
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our measures of quality and reporting were bespoke to the
trial design and the imbalance of trials to observational
data for covid-19 research will not fully explain the
findings.
To ensure a platform for the important emerging re-
search, standards for covid-19 submissions may have
been relaxed compared to non covid-19 submissions. It
could be argued that we should be more tolerant of po-
tential risk of bias when assessing covid-19 studies. We
acknowledge that covid-19 research was at an early stage
when we performed our review and methods may have
been modified accordingly. For example, given the un-
certain nature of covid-19 and potential treatments, full
blinding may have been considered too risky by investi-
gators and for observational studies it would be difficult
to know the most important confounder variables to
correct for in covid-19 analyses.
Strengths and limitations
We followed best practice guidance for meta-research
and used validated and objective scoring tools. Within
the time constraints of this rapid study, we created
Fig. 4 a, b Modified star plots, describing methodological quality (risk of bias) overall and for each domain of the risk of bias assessment tool for
differing study methods. a Randomised controlled trials (using Cochrane RoB1 tool). b Observational studies (using NHLBI tool). Blue spokes
represent covid-19 studies and orange spokes represent non-covid 19 studies. RCTS, randomised controlled trials; Obs studies,
observational studies
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training and calibration processes to ensure consistency
in assessment. It would not have been possible to mask
our raters to the covid-19 status of the papers under re-
view. Consciously or subconsciously, raters may have
preferentially marked down covid-19 research. To miti-
gate this risk, we embedded multiple checks of internal
validity throughout the review process.
Our choice of quality assessment tool was based on
explicit criteria and agreed by the group but we recog-
nise that there are a variety of tools available with no
consensus on the preferred approach [8]. While our
chosen tools were appropriate for most published stud-
ies, they were not always completely aligned with the in-
cluded study designs. For example, in our systematic
review category we used the generic AMSTAR (Asses-
sing the Methodological Quality of Systematic reviews)
[17] and PRISMA (Preferred Reporting Items for Sys-
tematic reviews and Meta-analyses) [10] tools to assess
reviews using network meta-analyses, individual patient
data and living systematic review designs, all of which
have their own quality assessment guidance [30–32].
A selection bias is possible. We did not attempt a
comprehensive analysis of all clinical research published
in the first wave of the pandemic, as this would involve
thousands of papers. Rather we selected exemplar, high
profile, weekly clinical journals who had published sub-
stantial numbers of covid-19 research papers. Although
the early covid-19 research was often shared with these
journals, we recognise that our included papers repre-
sent only a fraction of the totality of covid-19 research
published in the first wave.
Our study followed a pre-specified and publicly avail-
able protocol and was designed to assess a selection of
covid-19 papers published during the first wave of the
pandemic. Other approaches to an assessment of meth-
odological and reporting quality are plausible. For ex-
ample, we anticipated an imbalance of trials to
observational research methods in covid-19 and non-
covid research and did not attempt a matched case-
control design where the only difference was the covid-
19 subject matter. It could be argued that the ideal
method to assess the quality of covid-19 research would
be to compare the covid-19 papers with contemporan-
eous research describing an established but similarly in-
fectious and dangerous viral agent. While theoretically
possible, these designs would have been almost impos-
sible to deliver in practice during the first wave.
Quality of science is more than just valid methods and
transparent reporting. Indeed, in the covid-19 context,
other important factors like inclusiveness, data sharing
and clinical urgency may take precedence over rigid
rules on method and reporting. Even within our chosen
remit of methodological quality, there are many facets.
Some of our tools have a strict focus on internal validity
(bias) while others also consider external validity (gener-
alisability). Accepting all this, we do not claim to have
described a definitive measure of overall study quality,
but we have described and quantified fundamental as-
pects of conduct and reporting that should be main-
tained in all scientific publications. We believe this is
especially true when the topic matter is so important to
health and society.
Research in context
The volume of published clinical research is constantly
increasing, even more so, if we consider the pre-print
servers. It would not have been possible to assess the en-
tirety of the biomedical literature published during the
first wave of the pandemic. We limited to those journals
with the greatest clinical impact and considered to have
the highest standards. If there are concerns around qual-
ity in these four flagship journals, it seems likely these is-
sues will also permeate other journals. There is research
to support this view, studies of research methods, for ex-
ample prognostic modelling [33] and pharmacoepide-
miology [34], or research populations, for example older
adults [35], have all reported methodological concerns in
the covid-19 literature.
The story of hydroxychloroquine as a potential covid-
19 treatment is a pertinent example of the need for rapid
communication of science and the attendant risk of
sharing potentially biased research. Based on predomin-
antly observational studies, the drug achieved substantial
visibility and entered clinical practice [36]. Further ob-
servational studies suggested the benefits may have been
overstated and large RCTs now suggest the drug is
harmful [37]. Methodology and reporting were both
major factors in the rise and fall of this drug [38]. Recent
retractions and corrections of covid-19 hydroxychloro-
quine papers [39] also highlight a limitation in the scope
of our approach. Our assessment of quality can only in-
clude what is published and available to the public. Even
the best quality assessment tools will not pick up those
cases where there have been deliberate or inadvertent er-
rors in the research process.
Quality concerns are not an exclusive covid-19
phenomenon, and it is worth noting that our non-covid
papers also had biases. Issues with reporting, which were
prevalent in both covid-19 and non-covid studies, seem
less forgivable. Although differences in reporting quality
were not of the same magnitude as differences in meth-
odological quality, if anything, where research is pro-
duced at speed to answer an urgent clinical question,
then the need for comprehensive and fully transparent
reporting is even greater. All the journals assessed in this
analysis adhere to CONSORT recommendations for
RCTs and completion of a CONSORT checklist is
mandatory. Experience tells us that mandating a
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checklist is not a panacea. Since the introduction of
CONSORT, there have been improvements in trial
reporting, but poor reporting remains prevalent in con-
temporary research [40, 41].
Future research
We offer only a snapshot of the covid-19 evidence base from
the first wave of the pandemic. Our analyses of the effects of
time are limited by the relatively short period within which
we selected papers. As we move into second wave of the
pandemic and beyond, it would be interesting to repeat our
analysis looking for longer term temporal trends in quality.
Even within the period of this review, new concerns around
research publications are emerging. Using our approach to
look at pre-prints, inclusiveness or data sharing arrange-
ments would all be informative. We assessed various factors
that may be associated with research quality, but recognise
that many other plausible factors exist, some specific to
covid-19 and some common to all clinical research [42].
Conclusion
Covid-19 research published in major journals during
the first wave of the pandemic had methodological and
reporting issues that ultimately compromise the utility
of the research and may cause harm. The clinical re-
sponse to covid-19 has seen many examples of sacrifice
and tragedy. In clinical science we must not sacrifice re-
search quality in the race to publish data and it would
be further tragedy if current researchers and publishers
do not learn from the first wave of covid-19 research.
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